Poor
Not Aligned
Patient Risk:
High
Summary
No substantive alignment to the provided FDA label text can be verified because none of the extracted claims are supported by the supplied label sections (all are marked absent_from_label with no label citations). Several claims also appear to replace/modify labeling with external guideline or study statements, which are not verifiable against the label content provided.
Category Scores
Accurate Statements
Unsupported Statements
Early clinical trials and post-marketing reports linked statins with elevated alanine aminotransferase (ALT) and, rarely, fatal liver injury.
Marked absent_from_label with no FDA label section citation provided.
The FDA required a black-box warning and yearly LFTs for all statin users.
Marked absent_from_label with no FDA label section citation provided.
Meta-analyses found that the incidence of hepatotoxicity was <0.1% per year.
Marked absent_from_label with no FDA label section citation provided.
The FDA added a boxed warning on all statin labels in 2007.
Marked absent_from_label with no FDA label section citation provided.
The FDA urged LFTs every 3–6 months for patients >70 years, with comorbidities, or on concurrent hepatotoxic drugs.
Marked absent_from_label with no FDA label section citation provided.
A 2022–2023 National Cardiovascular Data Registry study reported an incidence of clinically significant ALT/AST elevations of 0.05% in 120,000 patients on atorvastatin for ≥1 year.
Marked absent_from_label with no FDA label section citation provided.
A 2022–2023 National Cardiovascular Data Registry study reported severe liver injury requiring hospitalization or liver transplant of <0.001% in patients on atorvastatin for ≥1 year.
Marked absent_from_label with no FDA label section citation provided.
Most LFT elevations were reported as mild and transient in the National Cardiovascular Data Registry study.
Marked absent_from_label with no FDA label section citation provided.
No clear causal link to atorvastatin dose was reported for LFT elevations in the National Cardiovascular Data Registry study.
Marked absent_from_label with no FDA label section citation provided.
A 2024 UK Biobank analysis reported an adjusted hazard ratio of 0.92 for any ALT/AST >3× ULN (non-significant) comparing statin users with matched non-users.
Marked absent_from_label with no FDA label section citation provided.
The 2024 UK Biobank analysis concluded that statins, including Lipitor, do not increase the risk of significant liver enzyme abnormalities.
Marked absent_from_label with no FDA label section citation provided.
A 2023 Cochrane review reported a risk of clinically relevant hepatotoxicity of 0.07% for atorvastatin versus 0.06% for placebo (no difference) with ≥5 years follow-up.
Marked absent_from_label with no FDA label section citation provided.
A 2023 Cochrane review reported serious liver events of 0.004% versus 0.003% (p = 0.78) for atorvastatin versus placebo.
Marked absent_from_label with no FDA label section citation provided.
An implication stated by the 2023 Cochrane review was that statins are not hepatotoxic at therapeutic doses.
Marked absent_from_label with no FDA label section citation provided.
Recent pre-clinical work reported that atorvastatin is largely metabolised by CYP3A4 in the liver.
Marked absent_from_label with no FDA label section citation provided.
Recent pre-clinical work reported that atorvastatin does not accumulate in hepatocytes to a level that would cause necrosis.
Marked absent_from_label with no FDA label section citation provided.
The liver enzyme elevations seen in clinical practice were reported as transient, dose-related, and reversible after drug discontinuation or dose reduction.
Marked absent_from_label with no FDA label section citation provided.
A 2024 study in Hepatology reported that inflammatory cytokines (IL-6, TNF-α) were elevated in a minority of patients.
Marked absent_from_label with no FDA label section citation provided.
A 2024 Hepatology study reported that elevated inflammatory cytokines were not associated with statin use.
Marked absent_from_label with no FDA label section citation provided.
ACC/AHA 2023 guidelines state there is no routine LFT monitoring unless the patient is >70 years old or has a history of liver disease, chronic alcohol use, or hepatitis.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
ACC/AHA 2023 guidelines recommend baseline LFT at initiation.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
ACC/AHA 2023 guidelines state follow-up LFT after 6–12 months is optional.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
ESC 2024 guidelines recommend baseline LFT.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
ESC 2024 guidelines recommend repeating LFT only if the patient develops symptoms (jaundice, fatigue) or if the dose is increased >10 mg/day.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
FDA 2025 states that the boxed warning remains.
Marked absent_from_label with no FDA label section citation provided.
FDA 2025 clarifies that serious liver injury is extremely rare (<1 in 10,000).
Marked absent_from_label with no FDA label section citation provided.
FDA 2025 states that routine monitoring is not required for low-risk patients.
Marked absent_from_label with no FDA label section citation provided.
The text states that most patients on Lipitor experience no clinically significant liver injury.
Marked absent_from_label with no FDA label section citation provided.
The text states that routine liver-function monitoring for everyone is no longer considered necessary by major cardiology societies.
Marked absent_from_label with no FDA label section citation provided; not verifiable against provided FDA label content.
The text advises that if experiencing jaundice, dark urine, severe abdominal pain, or fatigue, contact a doctor immediately due to possible liver injury.
Marked absent_from_label with no FDA label section citation provided.
The text states that LFT monitoring is more likely warranted with a high dose (>80 mg).
Marked absent_from_label with no FDA label section citation provided.
Contradictions
Important Omissions
FDA label-based boxed warning/Warnings & Precautions (5) content related to liver enzyme abnormalities and required monitoring or patient counseling, including any contraindications (4), dosing safety statements (2), and specific monitoring instructions.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The extracted claims make multiple safety- and monitoring-related assertions (boxed warning, monitoring schedules, incidence rates, symptom-triggered actions, dose thresholds) that are not supported by the supplied FDA label sections, so label-accurate safety communication cannot be ensured.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about FDA-required warnings and monitoring, numeric incidence rates, and guideline-derived monitoring schedules are not supported by the provided FDA label text (no citations; all marked absent_from_label).
Suggested Improvement
Restrict statements to the provided FDA label content for Lipitor (or the specific statin product) and cite the exact label sections (e.g., Warnings and Precautions 5.2 for liver enzyme abnormalities and Patient Counseling Information 17). Avoid attributing numeric risk estimates and monitoring intervals to FDA labeling unless explicitly present in the label text.